Mission Statement, Vision, & Core Values (2024) of Arbutus Biopharma Corporation (ABUS)

Mission Statement, Vision, & Core Values (2024) of Arbutus Biopharma Corporation (ABUS)

US | Healthcare | Biotechnology | NASDAQ

Arbutus Biopharma Corporation (ABUS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Arbutus Biopharma Corporation (ABUS)

General Summary of Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral infections and liver diseases.

Key Company Details:

  • Headquarters: Warminster, Pennsylvania
  • Founded: 2007
  • Stock Exchange: NASDAQ
  • Ticker Symbol: ABUS

Financial Performance

Financial Metric 2023 Value
Total Revenue $14.3 million
Net Loss ($82.4 million)
Cash and Cash Equivalents $77.1 million
Research & Development Expenses $49.2 million

Key Product Pipeline

  • AB-836: HBV RNA Therapeutic
  • AB-101: HBV Capsid Inhibitor
  • AB-729: RNA Interference Therapeutic

Primary Research Focus Areas: Hepatitis B Virus (HBV) treatments and liver disease therapeutics.

Industry Leadership

Arbutus Biopharma is recognized for its innovative approach in developing viral infection therapies, particularly in hepatitis B research.

Research Metric 2024 Status
Active Clinical Trials 3 Phase 2 Trials
Patent Portfolio 28 Active Patents
Research Collaborations 5 Active Partnerships



Mission Statement of Arbutus Biopharma Corporation (ABUS)

Mission Statement of Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Corporation focuses on developing innovative therapies for liver diseases, specifically hepatitis B virus (HBV) and other viral infections.

Core Components of Mission Statement

Component Specific Focus Key Metrics
Research Innovation HBV therapeutic development 4 active clinical-stage programs in 2024
Therapeutic Target Liver disease interventions $45.2 million R&D investment in 2023
Scientific Approach RNA interference technology 12 patent families in viral disease treatments

Research and Development Priorities

  • Develop novel HBV therapeutic candidates
  • Advance RNA interference platform technologies
  • Target chronic hepatitis B treatment strategies

Company Performance Indicators

Metric 2023 Value
Total Revenue $13.7 million
Research Expenditure $45.2 million
Cash and Investments $86.4 million

Strategic Pipeline Focus

Key Therapeutic Areas:

  • Hepatitis B virus (HBV)
  • Liver disease interventions
  • RNA interference technologies



Vision Statement of Arbutus Biopharma Corporation (ABUS)

Vision Statement Components of Arbutus Biopharma Corporation (ABUS)

Therapeutic Innovation Focus

Arbutus Biopharma Corporation aims to develop transformative therapies targeting viral diseases, specifically hepatitis B virus (HBV) and COVID-19. As of Q4 2023, the company has:

  • 3 active clinical-stage programs
  • $87.6 million in cash and cash equivalents
  • Market capitalization of approximately $166 million
Research and Development Strategy
Program Development Stage Target Disease
AB-836 Phase 1 HBV
AB-101 Preclinical HBV
DRACO-AMS Research Stage COVID-19
Strategic Collaboration Objectives

Arbutus maintains strategic partnerships to advance viral disease research:

  • Collaboration with Pfizer for HBV research
  • Ongoing licensing agreements in antiviral therapeutic development
  • Patent portfolio of 148 issued patents globally
Financial Performance Metrics
Financial Indicator 2023 Value
Total Revenue $14.3 million
Research and Development Expenses $56.2 million
Net Loss $67.4 million



Core Values of Arbutus Biopharma Corporation (ABUS)

Core Values of Arbutus Biopharma Corporation (ABUS) in 2024

Scientific Innovation and Excellence

Arbutus Biopharma Corporation demonstrates commitment to scientific innovation through focused research and development efforts.

R&D Investment 2024 Figures
Total R&D Expenses $45.2 million
Research Personnel 62 scientists and researchers
Active Research Programs 3 primary therapeutic areas

Patient-Centric Approach

Commitment to developing therapeutics addressing unmet medical needs.

  • Focused on hepatitis B virus (HBV) treatment
  • Developing novel RNA interference (RNAi) therapeutics
  • Prioritizing patient outcomes in clinical development

Ethical Research and Transparency

Ethical Research Metrics 2024 Compliance
Clinical Trial Transparency 100% registered on ClinicalTrials.gov
Regulatory Compliance FDA and EMA guidelines adherence
Ethical Review Board Approvals 7 independent review board certifications

Collaborative Scientific Ecosystem

Strategic partnerships and collaborative research initiatives.

  • 4 active academic research collaborations
  • 2 pharmaceutical industry partnerships
  • International research network engagement

Operational Excellence

Operational Performance 2024 Metrics
Total Operating Expenses $87.6 million
Cash and Investments $124.3 million
Research Productivity 2 advanced therapeutic candidates

DCF model

Arbutus Biopharma Corporation (ABUS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.